JPRN-UMIN000001722
未知
未知
A randomized, double-blind, placebo-controlled study of effect of green tea on lifestyle-related disease prevention - Effect of green tea on lifestyle-related disease prevention
Kakegawa Research Council for application of green tea in preventive medicine0 个研究点目标入组 60 人2009年2月21日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- metabolic syndrome
- 发起方
- Kakegawa Research Council for application of green tea in preventive medicine
- 入组人数
- 60
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •1\) Individuals with a medical record of heart failure or cardiac infarction. 2\) Individuals judged to have atrial fibrillation, Irregular Heart Beat, hepatic damage, kidney damage, cerebrovascular accident, rheumatism, diabetes mellitus, lipid disorder and/or anemia. 3\) Individuals with a medical record of allergy to food and drug. 4\) Pregnant women, or women with intending to become pregnant, and lactating women. 5\) Individuals judged by the doctor to be unsuitable.
结局指标
主要结局
未指定
相似试验
未知
3 期
A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agentsRheumatoid ArthritisJPRN-jRCT2080221561ovartis Pharma K.K.
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-PTYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasiaEUCTR2005-001627-11-ITYAMANOUCHI PHARMA882
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTOREEUCTR2005-001627-11-FIYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisMedDRA version: 20.0Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-002988-18-BESanofi-Aventis Recherche & Développement508